Tag Archives: MTC

PR Newswire

For 2020, The World Innovation Summit for Health (WISH) Delivers Leading Speakers and Compelling Discussions via an Immersive Virtual Platform

Leave a comment

DOHA, Qatar, Nov. 9, 2020 — The World Innovation Summit for Health (WISH) returns on 15 November, 2020, offering an impressive range of speakers, networking opportunities, discussions and presentations that explore global health challenges, and – all presented through a purpose-built 3D virtual platform.

Oscar-winning actor, humanitarian and activist, Morgan Freeman, keynote speaker at the World Innovation Summit for Health 2020 (Photo credit: Nigel Parry)
Oscar-winning actor, humanitarian and activist, Morgan Freeman, keynote speaker at the World Innovation Summit for Health 2020 (Photo credit: Nigel Parry)

In light of the current pandemic, the biennial global gathering of healthcare leaders is being held online, will be free to attend and, for the first time, members of the public are being invited to register. Additionally, WISH 2020 will take place over five days rather than the usual two, running from 15-19 November.

COVID-19 will feature prominently, as will a range of other global health challenges, including climate change and health, childhood toxic stress, mental health and digital technologies, and immunotherapy.

Confirmed speakers include the WHO director general, Dr. Tedros Adhanom Ghebreyesus; Sweden’s chief epidemiologist, Dr. Anders Tegnell; WHO COVID-19 special envoy, Dr. David Nabarro; award-winning, Sudan-based medic and humanitarian, Dr. Tom Catena; and California’s surgeon general Dr. Nadine Burke Harris.

Actor, activist and philanthropist Eva Longoria will add her voice to the discussions around the impact of the pandemic and global health inequalities experienced by women and girls of color. Iconic Oscar-winning actor Morgan Freeman will give a keynote speech around the topic of the need to focus on early childhood health in a world struggling to combat global warming and conflict.

More than 300 speakers and panelists have been confirmed so far, with more to be announced in the lead-up to the event.

Innovators and health entrepreneurs will be showcased in an expansive ‘Innovation Hub’ exhibition space, which will also feature organizations committed to building a healthier world, including The Carter Center, Save The Children, and UNICEF.

The WISH platform will also feature a library, a cinema, a networking area, and a wellness zone.

Sultana Afdhal, CEO of WISH, said: "This year more than ever, we have witnessed the importance of collaborating to tackle global health challenges. While we’re disappointed not to be able to welcome visitors to a physical event in Doha, we are looking forward to virtually welcoming many more people to WISH than would normally be possible."

WISH is an initiative of Qatar Foundation. More details regarding the summit, including details of how to register, can be found at www.wish.org.qa

Photo – https://mma.prnasia.com/media2/1329348/world_innovation_summit_morgan_freeman.jpg?p=medium600

 

PR Newswire

Clarivate Expands International Real-World Data Offering with Addition of Techtrials Brazilian Dataset

Leave a comment

Partnership to provide life science, healthcare and research professionals with comprehensive RWD capturing approximately 80% of the Brazilian population

LONDON, Nov. 2, 2020 — Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the expansion of international real-world data offerings through its partnership with Techtrials Pesquisa e Tecnologia Ltda (Techtrials), the leading healthcare real-world data (RWD) provider in Brazil. The new partnership will provide customers with comprehensive RWD capturing approximately 80% of the Brazilian population.

As part of the three-year partnership, Clarivate customers can access the largest integrated real-world database in Brazil to address the most pressing questions related to epidemiological, clinical and pharmacoeconomic outcomes. The dataset features in-depth, clinically structured, anonymized data of billions of records with more than 195 million patients in the public and private market as well as claims, electronic medical records, registry and lab data. The comprehensive Techtrials real-world data paired with the expertise, information and insights that power DRG healthcare products and services, will allow global researchers to access, synthesize and analyze critical data.

The Techtrials dataset will be available to life sciences companies internationally, supporting a multitude of end users, to enable deeper insights and delivery of complex and high value use cases.  Clients can choose from an array of delivery options depending on their resource needs and expertise, including: commercial targeting; patient population & market sizing; patient journey; therapeutic area assessments; disease burden analysis; health economics and outcomes research and more.

As the world’s 11th largest pharmaceutical market, Brazil spends 9.5 percent of GDP on healthcare – providing universal healthcare to its population.1 Multinational pharmaceutical companies continue to invest and expand operations in Brazil, with market researchers anticipating spending to increase at a compound annual growth rate of 7% to 10% from 2018–2022.2 Clarivate recognizes the ever-increasing need for customers within the Latin American market to have insights-ready RWD on a real-time basis to help drive and inform decision-making.

Ken McLaren, SVP & GM of Data, Analytics and Insights for Clarivate, said: "We appreciate the complexity of healthcare and the diversity of decisions its leaders must make, especially in an international context. We look forward to partnering with an organization like Techtrials to help our customers understand and drive decision-making with confidence in the high growth, high interest Brazilian market."

Douglas Andreas Valverde, CEO, Techtrials, said: "As a regional innovation leader for data solutions and real-world evidence, we offer a unique mix of capabilities and proprietary technology, providing valuable clinical and real-world evidence insights to support the efforts of pharmaceutical, healthcare and government agencies. We are proud to partner with Clarivate to reach international industry stakeholders who need to act and make critical decisions in their daily operations."

The Brazilian RWD offering features insights, including: new professionals per institution; variation of patients per period; procedures; workload by institution; comprehensive disease, epidemiology and market knowledge; drug use by specialty; outcomes, hospitalizations, surgeries and sub-procedures; hospital and comorbidities and more. The incorporation of Techtrials data further reinforces the expertise provided by Clarivate to support customers across the entire drug, device and medical technology lifecycles.

To learn more, visit https://clarivate.com/drg/real-world-data.

About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

Media Contact
Catherine Daniel
media.enquiries@clarivate.com

1National Health Account (NHA) Indicators 2020. Source: Global Health Expenditure Database (GHED) of the World Health Organization.
2"Brazil: Commercialization Outlook, Global Market Access Solutions" 2020. Source: DRG, part of Clarivate

Logo – https://techent.tv/wp-content/uploads/2020/11/clarivate-expands-international-real-world-data-offering-with-addition-of-techtrials-brazilian-dataset.jpg

Related Links :

Home
PR Newswire

CaDi introduces Lycofertilic™ – high potency, targeted supplements with algae DHA Omega-3 to provide anti-ageing support for the ovarian reserve and to prepare for egg retrieval and IVF

Leave a comment

LONDON, Oct. 23, 2020 — Cambridge Diagnostic Imaging (CaDi) is launching a new generation of targeted daily supplements, LycofertilicTM for fertility support and LycofertilicTM Prime to prepare for egg retrieval and IVF.

The ovarian reserve and egg quality of women declines with age. This depletion is exacerbated by stress, imbalanced diet and obesity and is further deteriorated by inflammatory pathologies of the pelvic organs. These processes, even on a subclinical asymptomatic level, are amogst the main factors negatively affecting natural or artificial fertilisation processes and pregnancy.

Lycofertilic™ has been developed by Lycotec, a company in Cambridge, UK. It is a patented complex of DHA Omega-3, Lutein and Zeaxanthin, which, due to patented technology, helps to provide anti-ageing support for the ovarian reserve in women throughout their fertility years.

It is very important to improve the quality of the egg in its preparation for retrieval and IVF. Lycofertilic™ Prime is an increased dose of this complex developed especially to boost this process.

Clinical trials (link below) demonstrated 250 mg of Lycofertilic™ DHA Omega 3 to be 10-16 times stronger than conventional Omega 3 supplement products and 4–5 times more powerful than Omega 3 pharmaceuticals. This superiority translates into a much more efficient reduction in markers of inflammatory damage and to a boost in peripheral tissue oxygenation and respiration. The increased bioavailability and targeted delivery reduces side effects and makes for unnecessary overconsumption of traditional Omega 3 products.

"According to the World Health Organisation 28 million women around the world encounter fertility problems every year. This is a serious problem which we decided to help to address by launching these new innovative technology-based products. As preparation for IVF is a critical period for the fertilisation process, it is of utmost importance that women receive health products with the highest quality ingredients such as algae DHA Omega-3, and of sustainable origin too" said Alexey Shulepov, CEO of CaDi.

A combination of Lycofertilic™ products with a personalised CaDi AI-based algorithm recommendation provides additional superior efficacy over existing Omega 3. Both Lycofertilic™ products are safe, vegan and their active ingredients are GMO-free and approved for humans.

About CaDi and Lycofertilic™:

http://cambridgediagnostics.co.uk – CaDi official website, online store of Lycofertilic™

lycotec.com – medical research company, developer of technologies of Lycofertilic™ 

https://www.ijabmr.org/article.asp?issn=2229-516X;year=2018;volume=8;issue=3;spage=148;epage=154;aulast=Petyaev – Clinical trials

For any questions please contact – pr@cambridgediagnostics.co.uk

PR Newswire

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Leave a comment

HONG KONG, Oct. 15, 2020 — Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation. This collaboration brings together Insilico’s state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho’s expertise in drug development, aimed to extend the human healthspan.

Insilico partners with Taisho
Insilico partners with Taisho

"We’re delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector. It is believed that aging is a universal phenomenon that we cannot stop. However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho’s validation platform to explore the new space of anti-aging solutions," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine

Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico’s co-ownership of the successfully developed programs under agreed payment.

"It is our great honor to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912. The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

About Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/global/

Media Contact

For further information, images or interviews, please contact:

ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

Photo – https://mma.prnasia.com/media2/1312850/insilico_taisho.jpg?p=medium600  

Related Links :

http://insilico.com

PR Newswire

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases

Leave a comment

Strategic partnership in brain imaging and AI

PARIS, MONTREAL, and QUEBEC CITY, Oct. 13, 2020 —

  • Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE
  • A strategic collaboration that covers 15 patents, including 9 issued in the U.S. and Canada
  • A unique technology alliance to improve clinical trials performance and personalize brain diseases management

QYNAPSE SAS, a French medical technology company, today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval. The objective of this strategic collaboration is to combine TPMD’s technologies, patents and expertise with Qynapse’s know-how and product line – and thus form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

The QyScore application
The QyScore application

Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (McGill University, Montreal, Canada) and Prof. Simon Duchesne (Université Laval, Quebec City, Canada) have established one of the most impressive scientific and technological asset bases in brain imaging and AI applied to this field, supported by more than 500 publications and scientific communications. These technologies are already being used in Canada by leading research consortia and private international players in studies specifically related to neurodegeneration, such as Alzheimer’s disease.

QYNAPSE is already marketing its first QyScore® medical device to clinical centers in Europe and the United States. Its platform is also used in clinical trials involving dozens of centers worldwide. The collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore® software to other brain diseases such as stroke, epilepsy, autism, schizophrenia, and head trauma – and also to develop new software to predict clinical progression for individual patients and optimize enrollment in clinical trials.

QYNAPSE’s acquisition of TPMD covers 15 patents, including 9 issued in the United States and Canada, grouped into nine technological asset families. The founders of TPMD will join QYNAPSE’s scientific board, setting the stage for a long-term collaboration.

According to Prof. Louis Collins: "QYNAPSE is a very promising partner for TPMD and both McGill and Laval universities, which will allow us to accelerate the regulatory approval and marketing of the technologies we have developed in recent years". Prof. Duchesne adds, "Indeed, with QYNAPSE we will have access to a partner that is already well established in the medical field. We look forward to providing clinicians with the tools they need to improve the accuracy of their diagnosis, facilitate prognosis and guide treatment for diseases such as dementias and cerebrovascular diseases."

"We are delighted to partner with two of the world’s leading experts in brain imaging, and to expand our scientific and clinical collaborations with two major centers of excellence in this field." said Olivier Courrèges, CEO of QYNAPSE. "This collaboration will create a unique technological structure, strengthening our ability to deploy powerful tools to address two major challenges: clinical trial performance and personalized management of brain diseases, which affect more than one in six people worldwide."

Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD’s scientific and commercial partnership contracts will be operated by this new entity.

About QYNAPSE

Founded in 2015, QYNAPSE is a French medical technology company, a spin-off from the CATI consortium of neuroimaging research laboratories. The company develops and markets solutions utilizing the potential of quantitative imaging and artificial intelligence to optimize diagnosis, prognosis and monitoring of patients with neurological diseases.
QYNAPSE is headquartered in Paris (France) and in Boston (USA).
www.qynapse.com 
www.qynapse.com/qyscore-software/ 

About TRUE POSITIVE MEDICAL DEVICES (TPMD)

Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off from the work of Prof. Simon Duchesne at the CERVO Brain Research Center and Université Laval and Prof. Louis Collins at the Montreal Neurological Institute and McGill University. The company designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases.
TPMD is based in Montreal and Quebec City (QC, Canada).
www.truepositivemd.com  

Logo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases-2.jpg
Photo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases.jpg

Media Contact
Ysé Sallé de Chou
Qynapse
ysalledechou@qynapse.com

PR Newswire

Life-changing medical innovations that makes the impossible possible

Leave a comment

STOCKHOLM, Oct. 8, 2020 — Medical wire that stops the trembling caused by Parkinson’s disease. Precision tools that can manufacture tailored prosthetic limbs durable and flexible enough to race down the slopes. And 3D-printing technologies that can create scull and spinal implants in just a few hours. With new and improved technology, the potential for helping people who suffers from physical disabilities have never been better.

The technological advancements within the medical sector are almost hard to grasp. At global engineering group Sandvik, one of the fastest growing segments today is Medical, where the company develops products and components that are essential in solutions that change people’s lives for the better.

In a series of films, Sandvik is celebrating some truly inspirational people that have been helped to live a normal life again after using advanced medical innovations and solutions. Click here to see them: home.sandvik/life-changing-innovations

"Our products in the medical field are rarely seen since they are often a part of the manufacturing process or imbedded in another device. Now we want to highlight the fascinating work happening within the medical sector and encourage more people and partners to look into some of these solutions and be inspired to advance the world of medical innovations even further," says Jessica Alm, Executive Vice President and Head of Communications at Sandvik Group.

Examples of disabilities where Sandvik’s innovations are a part of the life changing solutions are Diabetes, Parkinson’s disease, Hearing loss and physical injuries caused by accidents. Sandvik’s super thin medical wires, machining tools and cutting-edge knowledge within 3D-printing are important stepstones on the route back to a life with minimum impact from the disability.

But don’t take Sandvik’s word for it. Watch the in-depth films, starring persons that have experienced the emotional roller-coaster that comes with living with a disability, and struggling to find a way back to an everyday life.

For more information, contact: Martin Blomgren, Press and Media Relations Manager, email: martin.blomgren@sandvik.com phone: +46 70 577 0549

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/208/3212624/1316650.pdf

Life-changing medical innovations that makes the impossible possible

 

PR Newswire

Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market

Leave a comment

Allscripts enables enterprise-level, interoperability-aided EMR workflow adjustments and the subsequent clinical decision-making from a single window

SANTA CLARA, Calif., Oct. 7, 2020 — Frost & Sullivan has identified Allscripts, a global healthcare IT company, as a growth and innovation top-performing leader in the Frost Radar™: US Healthcare Data Interoperability Market, 2020. Allscripts demonstrates superior interoperability across the entire HIT ecosystem by enabling the direct integration of third-party clinical decision support applications into the company’s platforms through on-premise or cloud deployment models.

Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market
Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market

The global healthcare data interoperability market is valued at $4.92 billion in 2020, and the US market is projected to contribute $3.3 billion (67.07%). Frost & Sullivan expects departmental interoperability within a health system to remain significant during the COVID-19 pandemic because it facilitates the personalization of administrative, clinical, and financial intervention based on patients’ history of COVID-19 or proximity to regional hotspots.

To download the complimentary Frost Radar, please access: http://frost.ly/4mp.

"During and post-COVID-19, Allscripts’ EMR, patient engagement, population health management (PHM), and revenue cycle management (RCM) solutions can be made part of an integrated offering that can interface with external health systems, solutions and service providers, at scale and in near-real-time," said Koustav Chatterjee, Healthcare Industry Principal at Frost & Sullivan.

"We are honored to be recognized by Frost & Sullivan as an industry pioneer, as this ranking reflects our leadership in innovation and interoperability across the healthcare continuum," said Paul Black, Allscripts Chief Executive Officer. "Each day, our mission is to connect care across patient communities around the globe. At Allscripts, we believe healthcare should be Open, for Everyone™."

Frost & Sullivan found that Allscripts has practical, high-impact services that attain higher levels of scale in the United States. Allscripts is poised for further growth by:

  • Opening API initiatives, which are powered by the largest group of third-party API developers (4,000) in the US.
  • Augmenting its EMR capabilities and integrating cognitive interoperability standards across its HIT workflows.
  • Pioneering enterprise-level, interoperability-aided EMR (Sunrise EMR, TouchWorks® EHR) workflow adjustments and the subsequent clinical decision-making from a single window.
  • Incorporating SMART on FHIR (Fast Healthcare Interoperability Resources) across its product portfolio and strongly advocating the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) provisions (under the 21st Century Cures Act) for interoperability and patient access management.

Frost Radar™: US Healthcare Data Interoperability Market, 2020 provides results from an in-depth analysis built on a 360-degree research methodology where over 50 companies were evaluated. The team of industry analysts identified 11 industry leaders excelling at innovation, most poised for growth and ripe for investment, and recognizes them in the Frost Radar with insight into their innovative offerings, projected growth rates, strengths, and opportunities for the future.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Mariana Fernandez
Corporate Communications
Phone: +1 (210) 348.1012
Email: mariana.fernandez@frost.com

https://www.frost.com

Photo – https://techent.tv/wp-content/uploads/2020/10/frost-sullivan-recognizes-allscripts-as-a-growth-and-innovation-leader-in-the-united-states-healthcare-data-interoperability-market.jpg 

Related Links :

Frost New Home page v2

PR Newswire

Visiopharm Announces Scientific Advisory Board

Leave a comment

HOERSHOLM, Denmark, Oct. 6, 2020 — Visiopharm®, the Denmark-based leader in artificial intelligence-driven image analysis, tissue mining, and precision pathology has announced the formation of its scientific advisory board (SAB), comprised of industry experts in digital pathology, quality assessment, oncology, and immunology.

AI-driven Digital Precision Pathology is still a relatively new discipline. Compared to many other battle-tested modalities for diagnostics and research, there has been far less time and influx of resources for research and validation. It will take time, resources, and the sharpest scientific minds to unfold the true potential of this new technology, which has a great promise to fill an unmet need for precision medicine in cancer diagnostics.

"Collaborations within the framework of Scientific Advisory Boards is just one of many ways academia and industry can begin to work constructively together to explore, develop and document this new technology and its potential applications in the development of new drugs and companion diagnostic biomarkers. We are excited to be working with the scientific leaders in our field, under the leadership of Dr. Ralf Huss. And we look forward to contributing to the further advancement of AI-driven precision pathology within this forum," stated Michael Grunkin, CEO of Visiopharm.

Chaired by Ralf Huss M.D., Ph.D., certified Pathologist, professor of pathology, and managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg, Germany, the SAB is composed of ten additional luminaries that have extensive industry experience and bring world-class international expertise.

Ralf Huss, states: "The creation of a Scientific Advisory Board is great next step to leverage Visiopharm’s capabilities on how we practice pathology now and in the future on the highest level of clinical and scientific excellence with consistent and reliable quality. The SAB will steer Visiopharm’s solutions to improve cancer diagnostics, and given the complexity of tissue, find novel insights that are assisted by digital and AI-supported solutions." 

The members of Visiopharm’s SAB are as follows:

Marylin Bui M.D. Ph.D., Senior Member in the Department of Pathology and Scientific Director of Analytic Microscopy Core of Moffitt Cancer Center.  Professor and Director of the Cytopathology Fellowship at the University of South Florida, Tampa, Florida, USA.

Andrew Dodson, Director UK NEQAS Immunocytochemistry and In Situ Hybridisation (ICC & ISH), London/UK.

James L. Gulley, M.D., Ph.D., F.A.C.P., Chief Genitourinary Malignancies Branch, Head Immunotherapy Group, GMB, Director Medical Oncology Service, Center for Cancer Research, NCI, NIH, Bethesda/Maryland, USA.

David Harrison Ph.D., Professor of Pathology at the University of St. Andrews, UK, Director of iCAIRD.

Anne-Vibeke Lænkholm M.D., Clinical Research Professor and Senior Pathologist at Næstved-Slagelse Hospital, Næstved, Denmark.

Prof. Dr. med. Holger Moch, Director Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland.

Prof. Dr. rer. nat. Elfriede Nößner, Head of Immunoanalytics, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.

Anil Parwani M.D. Ph.D., Professor of Pathology, Vice Chair and Director of Anatomical Pathology, Director of the Digital Pathology, OSU, Columbus/Ohio, USA.

Bert Van der Vegt M.D. Ph.D., Histopathologist, University of Groningen, University Medical Center Groningen, The Netherlands.

Mogens Vyberg M.D., Professor of clinical pathology at the University of Aalborg, Copenhagen, Denmark.

The SAB will work with Visiopharm´s leadership team to provide scientific review and high-level advice to the R&D pipeline. The SAB will be involved in strategic discussions for research and pre-clinical solutions as well as the upcoming next-generation Precision Pathology tools for cancer diagnostics. With plans to accelerate diagnostic product development and establish global regulatory programs, the board will also guide these key initiatives.

Adrian Arechiga, Chief Marketing Officer at Visiopharm, commented, "The newly established SAB is an important step for the exciting future development of our research and diagnostic programs. The board members are pioneers in pathology, cancer research, and immunology, bringing unprecedented expertise, skills, and leading scientific perspectives that will guide Visiopharm´s ambitious growth strategy."

About Visiopharm A/S

Visiopharm® is a world leader in AI-driven Digital Pathology solutions. Visiopharms’ pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.

AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows.

Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, and the United States. Follow Visiopharm on Linkedin and Twitter. For other news, visit the Visiopharm Newsroom.

PR Newswire

Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020

Leave a comment

Digital POCT platforms will enable diagnostic testing beyond the clinic, transforming how assay results are gathered and analyzed, finds Frost & Sullivan

SANTA CLARA, California, Oct. 2, 2020 — Frost & Sullivan’s recent analysis, Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024, finds that the outbreak of the COVID-19 pandemic has transformed the infectious disease point-of-care testing (POCT) market. The emergence of cost-effective lab-on-a-chip and smartphone-based POCTs, alongside increasing reliance on less-invasive testing methodologies, will propel the POCT market. Globally, the infectious disease POCT market is estimated to witness more than a three-fold growth, reaching $26.4 billion by 2024 from $7.9 billion in 2019, up at a compound annual growth rate (CAGR) of 27.3%.

Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020
Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020

For further information on this analysis, please visit: http://frost.ly/4l1.

"The POCT instrument selection process should involve close collaboration with supply and clinical engineering departments to incorporate their input and feedback," said Amartya Bose, Healthcare Industry Analyst at Frost & Sullivan. "This is a key consideration when the POCT committee reviews all options and makes an informed decision. Hospitals/labs/pharmacies should select regional vendors for device procurement and services. This will reduce the procurement lead time and ensure devices are managed for quality assurance, timely calibrations, and interpretation of results."

Nitin Naik, Life Sciences Vice President at Frost & Sullivan, added: "The application of artificial intelligence (AI) and machine learning (ML) is a key growth opportunity for manufacturers to enhance their product portfolios. By leveraging these platforms, POCT assay menus can be expanded for different patient groups by simply iterating the product development cycle. U.S. healthcare providers are also leveraging digital POCT along with virtual assistants to screen and triage asymptomatic patients."

To capitalize on growth opportunities in the current and post-COVID-19 situation, POCT market participants should focus on the following solutions:

  • Multiplexed POCT: Integrate sample preparation and analysis within one device to offer more advantages in a competitive environment.
  • COVID-19 POCT: Develop accurate serology tests and mHealth-based diagnostics, as they will play a critical role in determining the disease’s full scope, combating the pandemic.
  • Digital POCT: Adopt cloud technologies as an integral part of device development to reduce the footprint and cost of POCT devices.
  • Millennials and sexually transmitted infections (STIs): Produce HIV/syphilis dual tests as evidence suggests a two- to five-fold increased risk of acquiring HIV if exposed to it when syphilis is present.

Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024 is the latest addition to Frost & Sullivan’s Healthcare research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024
K4C6

Contact:
Mariana Fernandez
Corporate Communications
P: +1 210 348 10 12
E: Mariana.Fernandez@frost.com
http://ww2.frost.com

Photo – https://techent.tv/wp-content/uploads/2020/10/smartphone-based-solutions-boost-the-global-infectious-disease-point-of-care-testing-market-at-an-explosive-cagr-of-70-2-in-2020.jpg

 

Related Links :

Frost New Home page v2

PR Newswire

Turning AI onto itself: AI algorithm detects when medical images will be difficult for radiologists or AI to make an effective diagnosis

Leave a comment

SAN FRANCISCO, Sept. 30, 2020 — A new AI algorithm can identify when medical images are likely to be difficult for either a radiologist or AI to make an effective diagnosis. The algorithm can potentially be used to triage medical scans and highlight cases that warrant further in-depth clinical evaluation or additional tests to support a definitive clinical diagnosis.

Radiologist diagnosing x-ray scan
Radiologist diagnosing x-ray scan

The algorithm, called UDC by AI healthcare company Presagen, was originally designed to automatically detect errors in medical data, particularly data that cannot be reliably verified by experts.

When applied to images of x-rays to detect pneumonia, errors by radiologists were rare when the x-ray images had clear features. However, UDC found the diagnosis (or label) for several x-ray images to be neither correct nor an error. Verification of these images by an independent radiologist also agreed that they were indeed difficult images to diagnose, with their independent assessment often disagreeing with the original diagnosis provided in the public dataset. Similarly, AI that was trained to diagnose pneumonia also found the assessment difficult for these images.

Removal of poor-quality (difficult) images identified by UDC from the training dataset improved AI accuracy for diagnosing pneumonia in x-rays images by over 10% as measured on a hold out blind test set, and the AI was shown to be more scalable (generalizable). The accuracy also exceeded benchmarks set by the current literature for that public dataset.

The AI Scientist that led the project, Dr Milad Dakka, said "Our results suggest these poor-quality images are uninformative, counter-productive or confusing when used in training AI. The ability to identify when new images are poor-quality is important to prevent an inaccurate AI clinical assessment, but also to alert the radiologist when the scan is likely to be difficult to diagnose or when a new scan should be taken."

Presagen Co-Founder and Chief Strategy Officer, Dr Don Perugini said "Many AI practitioners believe that AI performance and scalability can be solved with more data. This is not true, and we call it the AI data fallacy. Even 1% poor-quality data can impact the performance of the AI. Building accurate and scalable AI is about using the right data."

Presagen has recently developed a range of patent-pending AI technologies that drive a fundamental paradigm shift in developing commercially scalable AI products for real-world problems, which apply beyond healthcare and to AI more generally.

Dr Michelle Perugini said "We are excited to present to the world the suite of technologies, which we believe advance the field of AI. These technologies will allow Presagen to build scalable ‘out of the box’ AI products that are more commercially viable and technically superior, and thus market dominating. This is vital in Presagen’s journey to become world-leaders in AI Enhanced Healthcare and a dominant player in the AI-in-Femtech market globally. More importantly, we see it as an opportunity to change, lead, and dominate the AI industry."

 

Related Links :

https://www.presagen.com/